Serum Calprotectin – a NET Product – as a Biomarker of Disease Activity in Patients with Systemic Lupus Erythematosus: A Single-Center Case-Control Study from Poland

Iwona Homa-Mlak; Marcin Mazurek; Aleksandra Majdan; Radosław Mlak; Maria Majdan; Teresa Mełecka-Massalska

doi:10.12659/MSM.936534

13 July 2022: Clinical Research

Serum Calprotectin – a NET Product – as a Biomarker of Disease Activity in Patients with Systemic Lupus Erythematosus: A Single-Center Case-Control Study from Poland

Iwona Homa-Mlak ^1ACDEF* , Marcin Mazurek ^1BCEF , Aleksandra Majdan ^1DEF , Radosław Mlak ^1ACDE , Maria Majdan ^2ADEF , Teresa Mełecka-Massalska ^1ADEF

DOI: 10.12659/MSM.936534

Med Sci Monit 2022; 28:e936534

Authors information Article notes Copyright and License information

Background Material and Methods Results Discussion Conclusions References

View HTML version

Table 2 Differences in calprotectin value depending on demographic and clinical factors in the study group.

Variable	Median	p
Male	3.10	0.7735
Female	3.11	0.7735

Age (years)		0.0562
	3.14
>36.5	3.06

Duration of the disease (years)		0.8611
	3.11
>6	3.10

SLEDAI		0.6907
Mild and moderate	3.11
Severe	3.41

SLEDAI		0.2030
Mild	3.11
Moderate and severe	3.39

Calprotectin [ng/ml]		0.0013^*
Study group	3.11
Control group	2.45
^* Statistically significant results. SLEDAI – Systemic Lupus Erythematosus Disease Activity Index.

Back to the Article

Serum Calprotectin – a NET Product – as a Biomarker of Disease Activity in Patients with Systemic Lupus Erythematosus: A Single-Center Case-Control Study from Poland

Your Privacy